http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 06:48:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Telix+Pharmaceuticals+Ltd+%28TLX%3AAU%29+%28TLX%29+PT+Raised+to+AUD24.40+at+JPMorgan/26797896.html JPMorgan analyst Chris Cooper raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD24.40 (from AUD23.60) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Telix+Pharmaceuticals+Ltd+%28TLX%3AAU%29+%28TLX%29+PT+Raised+to+AUD24.40+at+JPMorgan/26797896.html Wed, 22 Jul 2026 06:48:24 -0400 TLX http://www.streetinsider.com/Intl+Ratings/Telix+Pharmaceuticals+Ltd+%28TLX%3AAU%29+%28TLX%29+PT+Raised+to+AUD24.40+at+JPMorgan/26797896.html JPMorgan analyst Chris Cooper raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD24.40 (from AUD23.60) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Telix+Pharmaceuticals+Ltd+%28TLX%3AAU%29+%28TLX%29+PT+Raised+to+AUD24.40+at+JPMorgan/26797896.html Wed, 22 Jul 2026 06:48:24 -0400 TLX http://www.streetinsider.com/Analyst+PT+Change/Telix+Pharmaceuticals+Ltd+%28TLX%3AAU%29+%28TLX%29+PT+Raised+to+AUD24.40+at+JPMorgan/26797896.html JPMorgan analyst Chris Cooper raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD24.40 (from AUD23.60) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Telix+Pharmaceuticals+Ltd+%28TLX%3AAU%29+%28TLX%29+PT+Raised+to+AUD24.40+at+JPMorgan/26797896.html Wed, 22 Jul 2026 06:48:24 -0400 TLX http://www.streetinsider.com/Analyst+PT+Change/Telix+Pharmaceuticals+Ltd+%28TLX%3AAU%29+%28TLX%29+PT+Raised+to+AUD24.40+at+JPMorgan/26797896.html JPMorgan analyst Chris Cooper raised the price target on Telix Pharmaceuticals Ltd (TLX:AU) (NASDAQ: TLX) to AUD24.40 (from AUD23.60) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Telix+Pharmaceuticals+Ltd+%28TLX%3AAU%29+%28TLX%29+PT+Raised+to+AUD24.40+at+JPMorgan/26797896.html Wed, 22 Jul 2026 06:48:24 -0400 TLX http://www.streetinsider.com/Corporate+News/Telix+publishes+Phase+1+prostate+cancer+therapy+study+in+Cancers+journal/26796373.html <p>Telix Pharmaceuticals (NASDAQ: TLX) announced the publication of results from its ProstACT SELECT Phase 1 study in <em>Cancers</em>, a peer-reviewed journal, according to a company statement.</p><p>The study evaluated TLX591-Tx (lutetium-177 rosopatamab tetraxetan), a prostate-specific membrane antigen (PSMA)-targeting radio antibody-drug conjugate therapy candidate for advanced metastatic castration-resistant prostate cancer (mCRPC). The primary objective was to assess whether gallium-68 PSMA-PET imaging could identify patients suitable for TLX591-Tx therapy using a theranostic approach.</p><p>The publication reports a median radiographic progression-free survival of 8.8 months in evaluable patients receiving TLX591-Tx in combination with standard of care. The authors noted the therapy demonstrated a manageable and http://www.streetinsider.com/Corporate+News/Telix+publishes+Phase+1+prostate+cancer+therapy+study+in+Cancers+journal/26796373.html Tue, 21 Jul 2026 17:00:52 -0400 TLX http://www.streetinsider.com/FDA/Telix+publishes+Phase+1+prostate+cancer+therapy+study+in+Cancers+journal/26796373.html <p>Telix Pharmaceuticals (NASDAQ: TLX) announced the publication of results from its ProstACT SELECT Phase 1 study in <em>Cancers</em>, a peer-reviewed journal, according to a company statement.</p><p>The study evaluated TLX591-Tx (lutetium-177 rosopatamab tetraxetan), a prostate-specific membrane antigen (PSMA)-targeting radio antibody-drug conjugate therapy candidate for advanced metastatic castration-resistant prostate cancer (mCRPC). The primary objective was to assess whether gallium-68 PSMA-PET imaging could identify patients suitable for TLX591-Tx therapy using a theranostic approach.</p><p>The publication reports a median radiographic progression-free survival of 8.8 months in evaluable patients receiving TLX591-Tx in combination with standard of care. The authors noted the therapy demonstrated a manageable and http://www.streetinsider.com/FDA/Telix+publishes+Phase+1+prostate+cancer+therapy+study+in+Cancers+journal/26796373.html Tue, 21 Jul 2026 17:00:52 -0400 TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Press+Releases/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html <ul><li style="text-align:justify;">Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2.</li><li style="text-align:justify;">Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile.</li><li style="text-align:justify;">TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer.<br/><br/></li></ul> <p align="justify">MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in <em>Cancers</em>, a peer-reviewed journal. http://www.streetinsider.com/Globe+Newswire/TLX591-Tx+ProstACT+SELECT+Study+Published+in+Cancers+Journal/26796358.html Tue, 21 Jul 2026 17:00:00 -0400 A.06822034 A.09642568 A.36051124 O.20026344 O.20371933 O.31276474 O.31712121 TLX TLX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Jun+30/26792077.html si-local-file:///var/storage/secattach/20260721/26792077.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Jun+30/26792077.html Tue, 21 Jul 2026 07:06:00 -0400 O.31276474 TLPPF TLX